Yes, Invega Sustenna Can Cause Erectile Dysfunction
Invega Sustenna (paliperidone palmitate) can cause erectile dysfunction, primarily through its mechanism of elevating prolactin levels, which is a well-documented adverse effect of this antipsychotic medication. This is explicitly stated in the FDA drug label and confirmed by clinical trial data 1.
Mechanism and Clinical Evidence
The erectile dysfunction associated with Invega Sustenna occurs through hyperprolactinemia—elevated prolactin levels that suppress testosterone production and directly impair sexual function 2. Most psychotropic drugs, including antipsychotics like paliperidone, can affect libido or erectile function either through direct action or by increasing prolactin or decreasing testosterone levels 2.
Documented Incidence from Clinical Trials
In schizophrenia trials:
- During the double-blind phase, 0.9% of males on Invega Sustenna experienced erectile dysfunction compared to placebo 1
- During the open-label phase, no single prolactin-related adverse reaction in males exceeded 2% 1
In schizoaffective disorder trials:
- 7.1% of males experienced prolactin-related adverse reactions during the 15-month double-blind phase, including erectile dysfunction 1
- During the 25-week open-label phase, erectile dysfunction occurred in 2.5% of males 1
Prolactin Elevation Pattern
The drug consistently elevates prolactin levels:
- In males with schizophrenia: 51.9% had prolactin elevations above reference range (>18 ng/mL) on Invega Sustenna versus 29.0% on placebo 1
- In males with schizoaffective disorder: 55.6% had elevations versus 23.2% on placebo 1
- Mean prolactin increased from 14.9 ng/mL at baseline to 24.7 ng/mL after treatment 1
Real-World Evidence
Recent pharmacovigilance data from the FAERS and JADER databases identified erectile dysfunction as a significant signal associated with paliperidone palmitate, with males being more prone to sexual dysfunction compared to females 3. A meta-analysis found sexual dysfunction occurred in 1% of patients, with the incidence entirely attributable to paliperidone (attributable risk equals incidence) 4.
Clinical Management Approach
When erectile dysfunction occurs on Invega Sustenna:
Confirm hyperprolactinemia: Check morning serum prolactin levels and total testosterone (if <300 ng/dL, diagnose hypogonadism) 5
Consider formulation switch: Switching from monthly to three-monthly paliperidone palmitate (PP3M) may reduce prolactin levels and improve sexual function due to less peak-to-trough concentration variation 6. One study showed significant decreases in prolactin levels (p<0.001) and sexual dysfunction scores after switching to PP3M 6
Evaluate medication alternatives: If sexual dysfunction persists and significantly impacts quality of life, discuss switching to an antipsychotic with lower prolactin liability with the prescribing psychiatrist
Treat the erectile dysfunction directly:
- First-line: PDE-5 inhibitors (sildenafil, vardenafil, tadalafil) are effective and well-tolerated 7, 8
- Start conservatively and titrate to maximum dose over at least 5 separate occasions before declaring treatment failure 7
- If testosterone is low (<300 ng/dL), testosterone replacement therapy may help, though this must be carefully considered in the context of the underlying psychiatric condition 5
- Second-line options include intraurethral alprostadil, intracavernous injections, or vacuum erection devices 7
Critical Counseling Points
Patients should be counseled at initiation that Invega Sustenna may cause erectile dysfunction and other sexual side effects (decreased libido, ejaculatory dysfunction) through prolactin elevation 1. They should be instructed to report these symptoms promptly, as they can significantly impact medication adherence and quality of life.
The sexual dysfunction is potentially reversible with dose adjustment, formulation change, or medication switch, and should not be dismissed as an inevitable consequence of antipsychotic therapy 9, 6.